UCB SA (OTCMKTS:UCBJY) Sees Significant Increase in Short Interest

UCB SA (OTCMKTS:UCBJY) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 13,900 shares, a growth of 363.3% from the February 13th total of 3,000 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 92,400 shares, the days-to-cover ratio is presently 0.2 days.

UCB Stock Performance

Shares of UCB stock traded up $1.56 on Wednesday, reaching $92.80. 26,542 shares of the company were exchanged, compared to its average volume of 41,870. The stock’s 50 day moving average price is $97.56 and its 200-day moving average price is $95.23. UCB has a 1-year low of $56.77 and a 1-year high of $106.60. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.